drugset / Trial / NCT03656393

To Evaluate the Efficacy and Safety of Gefitinib in Adjuvant Chemotherapy for Lung Adenocarcinoma

NCT03656393

Phase 3 Unknown 48 enrolled Shenzhen People's Hospital
Non-randomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study was to evaluate the efficacy and safety of targeted gefitinib versus oral vinorelbine and carboplatin in EGFR-mutant NSCLC patients.

Timeline

Start
2018-08-31
Primary completion
2020-07-31
Completion
2020-09-30

Drugs

EvaluationDrugModalityDoseRoute
Comparator Carboplatin Small molecule 5 unknown Intravenous
Subject Gefitinib Small molecule 250 mg Oral
Comparator Vinorelbine Small molecule 60 mg/m2 Oral